Veeva Systems Balances Strong Q1 With Cautious AI Bets - The Globe and Mail

The CRM vendors having a great quarter doesn't mean you are.

Veeva just reported strong Q1 numbers. Their Vault CRM is landing big pharma names like Merck KGaA and Teva, conversion rates are up, and they're being careful not to overpromise on AI. For a niche enterprise player built around life sciences compliance, it's a solid story.

But here's what that news actually signals: the vendors doing well are the ones that built deep for a specific industry — not the ones trying to be everything to everyone. Veeva wins because pharma reps have the same workflows, the same compliance needs, the same sales cycle. Their customers aren't asking for flexibility. They're asking for a system that mirrors their exact process out of the box.

That's the opposite of your situation. Your business doesn't work like your competitor's. Your sales motion, your customer segments, your follow-up logic — none of it maps neatly to a default template. And every time you've tried to force it to, you've ended up with workarounds your team hates and data your boss doesn't trust.

Veeva's success in pharma is a reminder that CRM only works when it's built around how you actually operate — not the other way around.

#CRM #SalesOperations #MidMarket #BusinessOperations #CRMStrategy

Original Source

Vault CRM Wins and High Conversion Rates. Vault CRM continued to gain ground with major global wins including Merck KGaA and Teva, pushing the live ...